Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/8/2025 | $72.00 | Buy | BTIG Research |
| 5/13/2025 | Buy | TD Cowen | |
| 5/7/2025 | $80.00 | Buy | Chardan Capital Markets |
| 1/23/2025 | $93.00 | Overweight | Piper Sandler |
| 1/10/2025 | Overweight | Cantor Fitzgerald | |
| 1/10/2025 | $85.00 | Buy | H.C. Wainwright |
| 11/26/2024 | $75.00 | Outperform | Robert W. Baird |
NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that the Company will participate in the following upcoming events: EVENT:Piper Sandler 37th Annual Healthcare Conference DATE: Wednesday, December 3, 2025 TIME:11:30am ET EVENT:2025 American Epilepsy Society Annual Meeting – Scientific Exhibit Session DATE:Sunday, December 7, 2025 TIME:2pm – 5pm ET About Bright Minds Biosciences Bright Minds Biosciences is
-- Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and Theresa V. Strong, PhD; distinguished global experts in PWS, will support the Company's PWS program, which was announced on November 6, 2025 -- NEW YORK and VANCOUVER, British Columbia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") today announced the addition of four global experts in Prader-Willi Syndrome (PWS) to its Scientific Advisory Board (SAB): Tania Markovic, MBBS PhD FRACPJennifer L. Miller, MDElizabeth Roof, H.S.P., M.A.Theresa V. Strong, PhD On November 6, 2025, the Company held a KOL event to announce the in
-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with Prader-Willi Syndrome -- -- Key Opinion Leaders (KOLs) participating on the call will include Theresa V. Strong, PhD., Jennifer L. Miller, MD, and Elizabeth Roof, H.S.P., M.A. -- -- Strong pre-clinical and clinical rationale supports potential of BMB 5-HT2C agonists to be the first on-target mechanism addressing both neuropsychiatric symptoms and hyperphagia -- NEW YORK and VANCOUVER, British Columbia, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Brig
4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
3 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
6-K/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
SCHEDULE 13G - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
BTIG Research initiated coverage of Bright Minds Biosciences with a rating of Buy and set a new price target of $72.00
TD Cowen initiated coverage of Bright Minds Biosciences with a rating of Buy
Chardan Capital Markets initiated coverage of Bright Minds Biosciences with a rating of Buy and set a new price target of $80.00
-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Stephen D. Collins, M.D., Ph.D., will join the Company as Chief Medical Officer (CMO), effective immediately. The Company also announces that Mark A. Smith M.D., Ph.D., will retire from his role as Acting CMO, but will continue to serve in an
-- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia -- -- Company has transitioned from a discovery to a development organization – -- Company to attend BIO-Europe Spring Conference in Basel, Switzerland, March 20-22, 2023 -- VANCOUVER, British Columbia, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for a
VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Dr. Doug Williamson has resigned from its Board of Directors. Dr. Williamson has accepted a new full-time role that precludes his participation on the Bright Minds Board. "In his short tenure on the Board, Doug's scientific, clinical, and medical experience has proven invaluable in supporting our efforts to develop the next generation of safe and efficacious drugs for challenging br
SC 13G - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
SC 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
SC 13D/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Conference call to be held on May 19, 2022, 10:00am ET -- VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, Dr. Revati Shreeniwas, Chief Medical Officer, Professor John McCorvy, PhD, Senior Advisor, and other key speakers will host a symposium on the recent therapeutic developments within the Dravet Syndrome landscape.